TARGET-G
LIVE

Serial Number

98463731

Owner

Bio Palette Co., Ltd.

Attorney

Subaru Ryan Kanesaka

Filing Date

Mar 22, 2024

Add to watchlist:

No watchlists yet
View on USPTO

TARGET-G Trademark

Serial Number: 98463731 • Registration: 7831428

TARGET-G is a trademark filed by Bio Palette Co., Ltd. on March 22, 2024. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Bio Palette Co., Ltd. (6 trademarks)

6-1, Otemachi 1-chome
Chiyoda-ku 100-0004 , JP

Entity Type: 03

Trademark Details

Filing Date

March 22, 2024

Registration Date

June 17, 2025

Published for Opposition

April 29, 2025

Goods & Services

Research and development in the field of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, product development advisory services, and scientific research advisory services relating thereto in the fields of protein, antibody, and microorganism scientific study, and the study of cells; structural and functional analysis of the genome with genome editing technology; DNA screening for scientific research purposes with genome editing technology; research and development, product development advisory services, and scientific research advisory services relating thereto in the field of genome editing technology; scientific research in the field of genetics and genetic engineering with genome editing technology; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; development of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; technical advisory services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; information services, namely, providing information relating to the development of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; scientific and technological services, namely, scientific testing, examination or research relating to medical treatment or medical technology with genome editing technology; information services, namely, providing information for scientific testing, examination or research purposes relating to medical treatment or medical technology with genome editing technology; scientific and technological services, namely, scientific testing or research relating to genome or gene to which genome editing technology is applied; scientific and technical research and technological development of bioinformatic tools in the fields of editing, modulation, modification, engineering, regulation, repair and therapy of gene, genome and cells to develop human pharmaceutical, biological preparations, and diagnostic products and services; research and development for the pharmaceutical industry and biotechnology industry with genome editing technology; research and development of biotechnology for others; research and development of genome editing technology for others; development of pharmaceutical preparations and medicines; biotechnology research; research and development in the field of genomics and biotechnology; technical advisory consulting services in the field of genomics and biotechnology; structural and functional analysis of genomes; scientific and medical research in the fields of gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy all to develop human pharmaceutical and biological preparations to be delivered or applied ex vivo to human cells for use in human therapeutics and diagnostic products and services; scientific study and research in the fields of gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy all to develop human pharmaceutical and biological preparations to be delivered or applied ex vivo to human cells for use in human therapeutics and diagnostic products and services; scientific and technological services, namely, design of bioinformatic algorithms for use in scientific and medical research in the fields of gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy all to develop human pharmaceutical and biological preparations to be delivered or applied ex vivo to human cells for use in human therapeutics and diagnostic products and services; testing, examination being inspection or research on agriculture, livestock breeding or fisheries

Filing History

POST REGISTRATION ACTION MAILED - SEC. 7
Apr 21, 2026 PRAM
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 20, 2026 APRE
TEAS SECTION 7 SURRENDER RECEIVED
Jan 28, 2026 ES7S
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jan 14, 2026 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 14, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 14, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 14, 2026 REAP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 17, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 17, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 29, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 29, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 23, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 1, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 24, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 24, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 24, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Dec 5, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Dec 5, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 4, 2024 GNRN
NON-FINAL ACTION E-MAILED
Oct 4, 2024 GNRT
NON-FINAL ACTION WRITTEN
Oct 4, 2024 CNRT
ASSIGNED TO EXAMINER
Oct 1, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 20, 2024 NWOS
NEW APPLICATION ENTERED
Mar 22, 2024 NWAP